Levodopa in the treatment of Parkinson's disease: Current controversies (multiple letters) [4]

Movement Disorders

Volumn 20, Issue 5, 2005, Pages 643-

  Gerlach, Manfred ^a,b   Reichmann, Heinz ^a,b   Riederer, Peter ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; LEVODOPA; LISURIDE; PERGOLIDE;

DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG UTILIZATION; DYSKINESIA; EVIDENCE BASED MEDICINE; HUMAN; LETTER; MARMOSET; MONKEY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RISK REDUCTION;

EID: 20944438242     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20435     Document Type: Letter

References (0)